![]()
|
|
||||||||
J. Biol. Chem., Vol. 281, Issue 1, 461-467, January 6, 2006
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||





1
From the
Laboratory of Molecular Pharmacology and ¶Laboratory of Medicinal Chemistry, Center for Cancer Research, NCI, National Institutes of Health, Bethesda, Maryland 20892 and the
Department of Chemistry and Chemical Biology, Harvard University, Cambridge, Massachusetts 02138
Integration is essential for retroviral replication and gene therapy using retroviral vectors. Human immunodeficiency virus, type 1 (HIV-1), integrase specifically recognizes the terminal sequences of each long terminal repeat (LTR) and cleaves the 3'-end terminal dinucleotide 5'-GT. The exposed 3'-hydroxyl is then positioned for nucleophilic attack and subsequent strand transfer into another DNA duplex (target or chromosomal DNA). We report that both the terminal cytosine at the protruding 5'-end of the long terminal repeats (5'-C) and the integrase residue Gln-148 are critical for strand transfer. Proximity of the 5'-C and Gln-148 was demonstrated by disulfide cross-linking. Cross-linking is inhibited by the inhibitor 5CITEP 1-(5-chloroindol-3-yl)-3-hydroxy-3-(2H-tetrazol-5-yl)-propenone. We propose that strand transfer requires a conformational change of the integrase-viral (donor) DNA complex with formation of an H-bond between the N-3 of the 5'-C and the amine group of Gln-148. These findings have implications for the molecular mechanisms coupling 3'-processing and strand transfer as well as for the molecular pharmacology of integrase inhibitors.
Received for publication, October 19, 2005
* This research was supported in part by the Intramural Research Program of NCI, Center for Cancer Research, National Institutes of Health. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
1 To whom correspondence should be addressed: Laboratory of Molecular Pharmacology, Bldg. 37, Rm. 5068, National Institutes of Health, Bethesda, MD 20892. Tel.: 301-496-5944; Fax: 301-402-0752; E-mail: pommier{at}nih.gov.
This article has been cited by other articles:
![]() |
I. Malet, O. Delelis, M.-A. Valantin, B. Montes, C. Soulie, M. Wirden, L. Tchertanov, G. Peytavin, J. Reynes, J.-F. Mouscadet, et al. Mutations Associated with Failure of Raltegravir Treatment Affect Integrase Sensitivity to the Inhibitor In Vitro Antimicrob. Agents Chemother., April 1, 2008; 52(4): 1351 - 1358. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Zhao, C. J. McKee, J. J. Kessl, W. L. Santos, J. E. Daigle, A. Engelman, G. Verdine, and M. Kvaratskhelia Subunit-specific Protein Footprinting Reveals Significant Structural Rearrangements and a Role for N-terminal Lys-14 of HIV-1 Integrase during Viral DNA Binding J. Biol. Chem., February 29, 2008; 283(9): 5632 - 5641. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. B. Dicker, H. K. Samanta, Z. Li, Y. Hong, Y. Tian, J. Banville, R. R. Remillard, M. A. Walker, D. R. Langley, and M. Krystal Changes to the HIV Long Terminal Repeat and to HIV Integrase Differentially Impact HIV Integrase Assembly, Activity, and the Binding of Strand Transfer Inhibitors J. Biol. Chem., October 26, 2007; 282(43): 31186 - 31196. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. K. Pandey, S. Sinha, and D. P. Grandgenett Transcriptional Coactivator LEDGF/p75 Modulates Human Immunodeficiency Virus Type 1 Integrase-Mediated Concerted Integration J. Virol., April 15, 2007; 81(8): 3969 - 3979. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. A. Johnson, C. Marchand, S. S. Patil, R. Costi, R. Di Santo, T. R. Burke Jr., and Y. Pommier Probing HIV-1 Integrase Inhibitor Binding Sites with Position-Specific Integrase-DNA Cross-Linking Assays Mol. Pharmacol., March 1, 2007; 71(3): 893 - 901. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. A. Johnson, J. M. Sayer, H. Yagi, S. S. Patil, F. Debart, M. A. Maier, D. R. Corey, J.-J. Vasseur, T. R. Burke Jr., V. E. Marquez, et al. Effect of DNA Modifications on DNA Processing by HIV-1 Integrase and Inhibitor Binding: ROLE OF DNA BACKBONE FLEXIBILITY AND AN OPEN CATALYTIC SITE J. Biol. Chem., October 27, 2006; 281(43): 32428 - 32438. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. A. Semenova, A. A. Johnson, C. Marchand, D. A. Davis, R. Yarchoan, and Y. Pommier Preferential Inhibition of the Magnesium-Dependent Strand Transfer Reaction of HIV-1 Integrase by {alpha}-Hydroxytropolones Mol. Pharmacol., April 1, 2006; 69(4): 1454 - 1460. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |